Newsletter sign up


Knowledge Center Our services

ADC Review
is made possible by:



Copyright 2014
Terms & Conditions


Profile Photo

About ADC Review

Articles by ADC

Duocarmycin analogues

26 November

[caption id="attachment_1192" align="alignleft" width="300"] Duocarmycin A[/caption] Chemical Name: 1,2,4,5,8,8a-hexahydro-4-oxo-2-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl)]-cyclopropa[c]pyrrolo[3,2-e]ind...

AbbVie Acquires Small API Site in Singapore

21 November

AbbVie, a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott, has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapor...


Monomethyl Auristatin E (MMAE)

Published on 31st October

Monomethyl auristatin E (MMAE)
Monomethyl auristatin E (MMAE)

Chemical Name: (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide

Molecular Weight: 717.98
Formula: C39H67N5O7
CAS#: 474645-27-7
Solubility: DMSO up to 20 mM

Biological Activity
Monomethyl Auristatin E (MMAE, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin. [1,2,3] MMAE is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself.

However, as part of an antibody-drug conjugate or ADC, MMAE is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to a specific, targeted cancer cell. The linker linking MMAE to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE and activates the potent anti-mitotic mechanism. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.[2,3,4,5]

Leave a Reply